Skott Martin, Gnech Michele, Hoen Lisette A 't, Kennedy Uchenna, Van Uitert Allon, Zachou Alexandra, Yuan Yuhong, Quaedackers Josine, Silay Mesrur Selcuk, Rawashdeh Yazan F, Burgu Berk, Castagnetti Marco, O'Kelly Fardod, Bogaert Guy, Radmayr Christian
Department of Urology, Section of Pediatric Urology, Aarhus University Hospital, Aarhus, Denmark.
Department of Paediatric Urology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
J Pediatr Urol. 2024 Feb;20(1):47-56. doi: 10.1016/j.jpurol.2023.09.005. Epub 2023 Sep 13.
Historically, ureteral reimplantation (UR) has been the gold standard for treatment of primary obstructive megaureter (POM) with declining renal function, worsening obstruction, or recurrent urinary tract infections. In infants, open surgery with reimplantation of a grossly dilated ureter into a small bladder, can be technically challenging with significant morbidity. Therefore, less invasive endoscopic management such as dilatation or incision of the ureter-vesical junction, has emerged as an alternative to reimplantation during the last decades.
To systematically evaluate the effectivity, safety, and potential benefits of endoscopic treatment (dilatation with or without balloon or incision) of POM in comparison to UR.
A systematic review was conducted. Randomized controlled trials (RCTs), nonrandomized comparative studies (NRSs), and single-arm case series including a minimum of 20 participants and a mean follow-up more than 12 months were eligible for inclusion.
Of 504 articles identified, 8 articles including 338 patients were eligible for inclusion (0 RCTs, 1 NRSs, and 7 case series). Age at time of surgery was minimum 15 days to a maximum of 192 months. Indications for endoscopic treatment (ET) included patients with loss of split renal function (>10%) and worsening of hydroureteronephrosis. The studies analysed reported a success rate ranging from 35% to 97%. Success was defined as stabilization of differential renal function without further procedures. A post-operative complication rate of 23-60% was reported (mostly transient haematuria, urinary tract infections and stent migration or intolerance). In 14% of the cases salvage UR following initial ET, was performed due to relapse of symptomatic POM.
Endoscopic treatment for persistent or progressive POM in children is a minimally invasive alternative to UR with a long-term modest success rate. Additionally, it can be performed within a wide age span, with equal success rate and complication rates.
从历史上看,输尿管再植术(UR)一直是治疗原发性梗阻性巨输尿管(POM)伴肾功能下降、梗阻加重或反复尿路感染的金标准。对于婴儿,将严重扩张的输尿管再植到小膀胱中的开放手术在技术上具有挑战性,且发病率较高。因此,在过去几十年中,诸如输尿管膀胱连接处扩张或切开等侵入性较小的内镜治疗方法已成为再植术的替代方案。
与输尿管再植术相比,系统评估原发性梗阻性巨输尿管内镜治疗(扩张,有或无球囊,或切开)的有效性、安全性和潜在益处。
进行了一项系统评价。纳入标准为随机对照试验(RCT)、非随机对照研究(NRS)和单臂病例系列,每组至少20例参与者,平均随访时间超过12个月。
在检索到的504篇文章中,8篇文章(共338例患者)符合纳入标准(0篇RCT,1篇NRS,7篇病例系列)。手术时年龄最小15天,最大192个月。内镜治疗(ET)的适应症包括分肾功能丧失(>10%)和肾盂输尿管积水加重的患者。分析的研究报告成功率在35%至97%之间。成功定义为分肾功能稳定,无需进一步手术。报告的术后并发症发生率为23%-60%(主要为短暂性血尿、尿路感染和支架移位或不耐受)。在14%的病例中,由于症状性原发性梗阻性巨输尿管复发,在初始内镜治疗后进行了挽救性输尿管再植术。
儿童持续性或进行性原发性梗阻性巨输尿管的内镜治疗是输尿管再植术的一种微创替代方法,长期成功率适中。此外,该方法可在较宽年龄范围内实施,成功率和并发症发生率相当。